Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates
“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.
Dr. Moran credits the baby boomer generation with this awareness in action. Whether it’s through social media or simply talking to a friend, patients are being introduced to brachytherapy through channels that weren’t available 10 years ago. Dr. Moran hopes to use these new channels to share patients’ stories and testimonials.
The more widely those stories are shared, the greater the opportunity for more men to take an active role in their treatment and reaching optimal quality of life thereafter.
That said, Dr. Moran notes that the internet is not always a reliable source and that he hopes to always provide patients with the most accurate and valuable information when making their treatment decision.
If you would like to learn more about how brachytherapy improves outcomes for many types of cancer patients, especially prostate cancer patients, contact firstname.lastname@example.org.
American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131
RICHLAND, WASHINGTON – September 28, 2021 – The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131...
Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues
Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options...
Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...